Introduction
Modern methods of gene analysis can be applied to many fields of medicine. This presentation attempts to assess the impact of gene analysis on clinical chemistry, äs seen by a clinical chemist. The discussion focuses on three topics:
(1) methodologieal characteristics, (2) some of the applications of gene analysis, and (3) the public debate äbout the impact of gene analysis on the individual and society.
Methodology
Several aspects of polynucleotide hybridization technology need to be fürther developed' for routine use in clinical chemistry. The mäin goäls for tihis development are to increase the specificity, sensitivity, and speed of analysis, to make the use of radioactive labelling unnecessary, to automate analysis, and to increase the cost/benefit ratio. Table l reviews the different procedures of hybridization technology. Some subheadings have been added under the "Southern blot" technique to demonstrate the improvements in cleavage and Separation of PNA/RNA. The* Southern blot technique is addressed in figure l, which depicts in a very simplified way the two basic forms of application:
direct analysis, with probes hybridizing directly on, the position of a gene defect, and indirect analysis, with probes hybridizing in a position close to, but not directly on, the gene defect itself. The latter is called restriction fragment length polymorphism (RFLP) analysis, because the length of the DNA fragment visualized with the probe differs depending on the presence or absence of a gene mutation.
Today only a few gene defects can be analyzed with direct probes; indirect restriction fragment length polymorphism methodology has to be used for the majority of tests (8) . This technique, however, only provides statistical evidence: a positive or negative test result is based on the establishment by analytical and biostatistical methods of a reliable correlation A probe is available binding in some distance from the gene mutation. When the mutation eliminates the restriction cleavage site, the probe will mark a band of higher molecular weight in the Separation gel. Normals show a band of lower molecular weight, homozygous patients show a band of higher molecular weight, heterozygous carriers show both bands. N = normal person, H = heterozygous carrier, A = affected homozygous patient, = gene mutation ("linkage") between appearance of a defmed restriction fragment and a gene defect (l, 9) . This is usually achieved by moving the probes stepwise closer to the gene defect ("gene walking, gene jumping") until a "direct" probe has been found (10). (13) .. The sensitivity of predicting the risk for Hunfington's disease by testing for a direct Huntington marker would be nearly 100%, because this disease has an almost absolute penetrance (14) .
*-Genetic constellation ofthefamily:
The linkage of diseäses with genetic markers depends upon the genetic constellation of a family; it is "family specific". Assessment of the risk for genetic diseäses with restriction fragment length polyinorphism markers is only possible after the linkage has been estäblished by testing äs many members of the patients family äs possible (15).
-Linkage of marker genes with gene defects: This affects the error probability öf gene analysis. The Problem has already been addressed with regard to restriction fragment length polymorphism methodology. The linkage depends upon the distance between the gene defect and the marker Position. The greater the distance, the greater the probability of a crossing over during the meiotic phase of cell division, resulting in uncoupling of the marker from the defect position. The unit of measure for this distance is the Morgan: one centiMorgan is equivalent to about one million base pairs, and this distance is -with notable exceptions -equivalent to a crossing over probability of 1%, which means an error probability of 1% (16) . For instance, the Huntington marker of Gusella (1983) binds at a distance of 5c-Morgan from the gene defect. Therefore the sensitivity of a positive test with this marker is 95% (14) . A good marker should be positioned at a distance of less than 0.2 c-Morgan from the gene defect, which translates to a sensitivity of 99.8% (9) . The sensitivity can be improved considerably by using two probes binding on both sides of a gene defect.
Some methodologcical factors that have significant effects on the sensitivity and specificity of hybridization assays are the choices of technique and labelling system, degree of Separation attained, length of the DNA used äs a probe, and the nucleic acid selected for hybridization. Most of these problems are self-evident to the clinical chemist, so only two of them will be addressed further.
-The signal-generating label system used is directly responsible for the assay sensitivity. Table 2 shows a few examples of the large variety of labels published. The Standard label is 32 P, resulting in an absolute sensitivity of 0.5 pg DNA. In recent years, great effprts have been made to develop non-radioactive detection Systems. With the most elaborate enzyme-labelled biotin-avidin Systems, a sensitivity of l pg DNA is routinely obtained. It is only a matter of time until non-radioactive labels will be aVailable that give equal or better sensitivity than the 3 *P label.
Tab. 2. Gene analysis: Labeling of probes (3, 17, 18) .
Radioactive labels DNA - -Assay sensitivity and specificity can be greatly enhanced by hybridization with nucleic acid species other than chromosomal DNA. This list will certainly be extended in the future.
The applications for DNA/RNA probe techniques are expanding\rapidly. Table 5 gives a -necessarily incomplete -list of such applications. A few of these applications which are of special interest for the clinical chemist will be discussed in some detail.
Prenatal and carrier diagnosis of genetic diseases is no topic of this review. It in principle is connected with genetic counseling and therefore is a domain of the human geneticist. It should be realized that environmental diseases have a multifactorial etiology. In addition to genetic predisposition, factors such äs the lifestyle öf the individual have a significant influence on the development of these diseases. The problems of screening programs, which are well known to the clinical chemist, also apply to preventive genetic analysis. The task is not only to identify the carrier of a genetic defect, but to identify carriers of the defect who are prpne to develop disease. The measure for this probability is the "relative risk". It equals the percentage of defect carriers with disease manifestations, divided by the percentage of defect carriers without disease manifestations. Thus, a predictive valüe of a positive test in excess of 0.9 can only be obtained in patient samples in which the prevalence of defect carriers is greater than 10% and with markers indicating a relative risk of more than 100 (39) . In addition* increasing knowledge about the heterogeneity of gen etic defects (see e.g. I.e. (12)) leads to a further complication in defining individual "genetic predisposition". Therefore. the value of preventive genetic health screenirig will be restricted to carefülly selected risk groups. A widely discussed example is Occupational screening'. the attempt to assess the risk for employees ("hypersusceptibility") by detecting genetic predispositions for Occupational hazards, e. g., exposure to chemicals, air pollution, or extreme stress situations. Some chemical companies, äs well äs some government agencies in the U. S., have been utilizing such tests. However, äs has been pointed out with regard to preventive health testing, the problems of multifactorial etiology and statistical significance apply to oecü-pational testing. In addition, the genetic markers tested are not necessarily associated with susceptibility, and no cost/benefit analyses have been performed. Accordingly, the responsible authorities have stopped performing these tests in most cases. Intensified ecogenetic research is necessary to provide a firm basis for such activities (14, 25, 40) .
A field of great promise is pharmacogenetics. The possibility to determine the "genetic phenotype" of patients regarding their response to drugs certainly will be an important step in optimizing chemptherapy.
It is of considerable interest to the work of the clinical chemist to note how laboratory testing in the field of malignant diseases will be influenced by the hybridization technique. It is difficult to predict the extent to which gene analysis will advance the use of biochemical techniques in cancer management. However, in some cases the use of DNA probes has already been proven to have a definite advantage in the detection or differential diagnosis of cancer, äs shown in The detection of malignant B-cell clones is important in the differential diagnosis of non-Hodgkin lymphomas. Today, DNA probes are available for particular regions of chromosomal immunoglobulin genes. New restriction patterns are constantly being generated äs a consequence of intrachromosomal gene rearrangement; the cell-specific IgO molecüle is a different one in each new Bcell clone. Normally, these clonal immunoglobulin species cannöt be deteeted by restriction analysis, because the fractipn of each new B-cell clone is too small to be deteeted. However, if a malignant clone increases to constitute more than l % of the total clone populatioru its band in the hybridization assay becomes prominent.
Detection of chromosome translocations is of definite value in the differential diagnosis of leukaemia induced by activated oncogenes. For example, proof of the translocation of sis and abl oncogenes between chromosornes 9 and 22 is a definitive marker in the diagnosis of chronic myelocytie leukaemia. Today testing is done by cytogenetic techniques (including DNA probes), but probes for use in the restriction fragment length polymorphism technique are being developed. The problem is that in the process of translocation the points at which chromosornes break vary over a distance of about 25 kilobases; this leads to some ambiguity in the evaluation of restriction fragment length polymorphism patterns.
A straightforward application of hybridization assays is the detection of foreign RNA and DNA to diagnose bacterial and viral infections in humans. Accordingly, much effort is being spent to develop routine techniques for use in medical microbiology. It can be anticipated that these methodological shortcomings will be resolved within a short time.
An example of the use of DNA probes in medical microbiology is their application in the diagnosis of bacterial infections, In addition to increasing the sensitivity and speed of analysis, emphasis has been placed on developing more specific assays. For instance, by using probes for plasmid DNA, evidence can be obtained about the antibiotic resistance patterns (21), or about specific auxotypes (32) . In addition, by using probes specific for toxin genes, evidence can be generated about the ability of E. coli to produce endo-and exotoxins.
Implications for the Clinical Chemist
Because of the many areas to which hybridization assays can be applied, the clinical chemist is interested in learning what impact these new techniques might have on his laboratory, and when. In the course of the controversy about the merits and risks of modern biology, the public has been made aware that gene analysis is a technique which could be used to infringe upon the basic rights of the individual. In many ways this debate has become irrational and emotional (14, 28, 46, 47) . For example, the use of gene analysis in occupational screening could be considered preventive medicine, but it could also be used for genetic exploration of employees or to bar certain classes of employees froin holding certain positions.
To identify aspects of the controyersy on which the clinical chemist iriust take a position, it is necessäry to look at the arguments rationally. Table 9 shows some points that must be considered in evaluating the impact of gene analysis on the individual and ön society. As can be seen, arguments have been presented for and against these points. One example is the area of "social aspects." It is valid to ask about the extent to which society should carry the bürden for groups with "protected handicaps." An ärgument could be made in fävor of large scale prenatal and preventive screening; an eqüally valid counter-argument is the duty of society to care for its disabled and diseased, which is even included in the German constitution (52) . Another exainple is the area of "data protection." The duty of the authorities to protect citizens from härm would lead to a System of disease prevention coupled with some degree of social pressure and handling of personal data. This is counterbalanced by the right to selfdeterminätion, an ärgument based on the rights of Personality that denies to authorities any right to acquire or utilize personal data. At present there is no consensus on the arguments about gene analysis. As a result, various groups have formulated pölicies about how gene analysis should be handled (53, 54).
The clinical chemist searching for guidelines for bis involvement in gene analysis should particularly consider ethical questions concerning the analysis and Interpretation of the human genome (46, 49, 50, 51, 55, 56) . These questions include the rights of individuals äs opposed to the rights of society, and protection of the ill and disabled. Arguments concerning "genetic health" are irrelevant because the effects of genetic counseling, äs the experts agree, will not change to a significant degree the gene pool of our population. According to Professional authorities in the field of ethics, it will not be necessary to formulate special "gene ethics," because all problems can be solved by means of existing medical ethics (56) . Rules that the clinical chemist can follow in his work include adherence to the responsibility principle of ethics. This means that he has to consider and to take the responsibility for the possible consequences of his work (50, 51, 57) . It is considered necessary to attain i consensus of the scientists engaged in gene analysis j by involving the medical ethics commissions (48, 52) . i
An objective and detailed consideration of ethical problems in gene analysis was provided by the 1983 report of the President's Commission for the Study of Ethical Problems in Medicine and Biomedical and Behavioral Research (58) . The commission advocates that five conditions be met to ensure the use of gene analysis to benefit the individual. These conditions are confidentiality, autonomy (individual choice), knowledge (instruction), well-being (usefulness via well organized programs), and equity (equal access of all groups). However, the Commission also believes that overemphasis on individual rights may cause härm to other persons, e. g., children or the disabled. In such cases, it may be necessary to perform lowrisk procedures.
Another set of recommendations, also covering the implications of gene analysis, was developed in 1985 by the International Conference on Bioethics in France (59) . Meanwhile, the report of the EnqueteKommission "Chancen und Risiken der Gentechnologie" (61) has been published, which contains a detailed analysis of the Situation in Germany. Special reference to the Situation of the clinical chemist will be given in the document "The Role and Responsibilities of the Clinical Chemist" which is being prepared by IFCC (60) .
In spite of all questions and problems connected with the application of gene analysis to human beings, in an educated society it could lead to an improved quality of life, äs the President's Commission foresees (58) : "In sum, the fundamental value of genetic screening and counselling is their ability to enhance the opportunities for individuals to obtain Information about their personal health and childbearing risks and to make autonomous and noncoerced choices based on that Information."
